ArticleExperimental hematology & oncology2022

A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.

Nobuhiko Nakamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.